New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM). This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations. In this exclusive, Special Edition MTT episode, our academic and community oncology experts will explore the following key points:
- Emerging evidence, rationale, and clinical implications for the use of CAR T-cell therapy in the early versus late stages of relapse, with insights into how disease biology and overall outcomes differ among these patient populations(eg, high-risk, early relapse, TCE, etc).
- Best practices for fostering interprofessional collaboration between cellular therapist facilities and community oncology practice settings, focusing on strategies to enhance teamwork as a means to enhance patient care and optimize the use of CAR T-cell therapy.
- Approaches to ensure timely referral and initiation of treatment through clinical trials, specifically focusing on reaching patients from underrepresented communities, facilitating access and representation to CAR T-cell therapies in clinically appropriate patients.